Drug intelligence / Profile preview

LNK-007

Development stage: Discontinued
Lead developer: Lynk Pharmaceuticals
Modality: Small Molecules

Overview

LNK-007 is an investigational small-molecule RAS pathway modulator that was initially developed by Lynk Pharmaceuticals for oncology indications. Publicly available pipeline data categorize it under “RAS modulators,” implying that it was designed to interfere with aberrant RAS signaling, a key driver of tumor cell proliferation and survival in multiple solid tumors and hematologic malignancies, although its precise target, binding mode, and pharmacology have not been disclosed.[7] Development of LNK-007 has been discontinued and no active clinical trials or approved indications are currently reported.[7]

Targets

MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on LNK-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNK-007.

Explore the full profile